The Rising Influence of Rising Affluence

[DewDiligence]

AZN sales in China are booming—despite lackluster RoW results:

https://uk.reuters.com/article/uk-astrazeneca-results-china/astrazeneca-rides-china-wave-as-rival-glaxosmithkline-struggles-idUKKBN1D91RR

China revenue in the third quarter increased by 12 percent at AstraZeneca and the country now accounts for 15 percent of its global product sales - a far higher proportion than at other big pharma companies.

… straZeneca has had five new products recently added to the country’s National Reimbursement Drug List - Onglyza for diabetes, cancer drugs Iressa and Faslodex, heart medicine Brilinta and antipsychotic treatment Seroquel.